Galectin Therapeutics (GALT) Convertible Debt (2021 - 2026)

Galectin Therapeutics' Convertible Debt history runs 6 years deep, the most recent figure standing at $32.9 million for Q1 2026.

• On a quarterly basis, Convertible Debt rose 204.06% year-over-year to $32.9 million in Q1 2026; TTM through Mar 2026 was $32.9 million, a 204.06% increase from a year earlier, with the FY2025 full-year figure at $32.7 million, up 204.69% from the prior year.
• Convertible Debt improved to $32.9 million in Q1 2026 per GALT's latest filing, from $32.7 million in the prior quarter.
• Across five years, Convertible Debt topped out at $32.9 million in Q1 2026 and bottomed at $10.7 million in Q4 2024.
• The 5-year median for Convertible Debt is $30.3 million (2023), against an average of $27.7 million.
• Across the five-year window, Convertible Debt soared 205.96% in 2022 and sank 65.28% in 2025, its largest moves.
• Year by year, Convertible Debt stood at $30.0 million in 2022, then grew by 3.13% to $30.9 million in 2023, then tumbled by 65.27% to $10.7 million in 2024, then soared by 204.69% to $32.7 million in 2025, then climbed by 0.54% to $32.9 million in 2026.
• Per Business Quant, the three latest GALT Convertible Debt figures stand at $32.9 million (Q1 2026), $32.7 million (Q4 2025), and $32.3 million (Q2 2025).